Vir Biotechnology, Inc. reported significant financial improvements in its latest quarterly results, with total revenues reaching $238.9 million for the three months ended June 30, 2026, compared to just $1.2 million in the same period last year. This surge in revenue was primarily driven by a $239.3 million upfront payment from a collaboration agreement with Astellas US LLC. The company also recorded a net income of $80.1 million, a stark contrast to a net loss of $111.0 million in the prior year, marking a substantial turnaround in profitability.

In terms of operational metrics, Vir Biotechnology's research and development expenses increased to $135.3 million for the second quarter of 2026, up from $97.5 million in the same quarter of 2025. This rise is attributed to heightened activities related to its chronic hepatitis delta and oncology programs, including costs associated with contract manufacturing and clinical trials. The company’s total operating expenses for the quarter were $165.5 million, compared to $119.6 million in the previous year, reflecting the ongoing investment in its clinical pipeline.

The company has also made strategic advancements, including the completion of its Phase 3 ECLIPSE 2 trial for chronic hepatitis delta, which is now fully enrolled. The ECLIPSE program aims to evaluate the efficacy of its treatment regimen, with topline data expected in late 2026 and early 2027. Additionally, Vir Biotechnology has initiated a global collaboration with Astellas to co-develop the investigational drug VIR-5500 for prostate cancer, further expanding its oncology portfolio.

As of June 30, 2026, Vir Biotechnology reported total assets of $1.2 billion, up from $1.0 billion at the end of 2025, bolstered by cash and cash equivalents of approximately $278.7 million. The company’s employee headcount has also increased, reflecting its growth and expansion efforts. Looking ahead, Vir Biotechnology anticipates continued investment in its clinical programs and expects to maintain sufficient liquidity to fund operations for at least the next twelve months, supported by its recent capital raises and collaboration agreements.

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is a biopharmaceutical company focused on developing therapies for infectious diseases and cancer. Its core activities include discovering and engineering antibodies, T-cell engagers, and siRNA treatments targeting hepatitis B, hepatitis delta, HIV, and solid tumors. Leveraging immunology, AI, and proprietary platforms, it aims to create innovative, targeted, and safer medicines to address high unmet medical needs worldwide.

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov